Research programme: RNAi therapeutics - Alnylam/Ionis

Drug Profile

Research programme: RNAi therapeutics - Alnylam/Ionis

Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals; Isis Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Small interfering RNA
  • Mechanism of Action 5 aminolevulinate synthetase inhibitors; Antithrombin III inhibitors; Apolipoprotein A inhibitors; Factor XI inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Acute intermittent porphyria; Atherosclerosis; Haemophilia; Hyperlipoproteinaemias; Venous thromboembolism

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 15 Jan 2015 Research programme: RNAi therapeutics - Alnylam/Isis is available for licensing as of 15 Jan 2015.
  • 09 Jan 2015 Alnylam and Isis expand their collaboration with an intellectual property cross licensing agreement for development of RNAi therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top